Igm Biosciences, Inc.

Trellis Bioscience, Inc.

Igm Biosciences A/s

Fen Zhang

Bruce Alan Keyt

Leonard G Presta

Ramesh Baliga

Lawrence M Kauvar

Orit Foord

Krista Maureen McCutcheon

Ying-Ping Jiang

William Usinger

Gizette Sperinde

Minha Park

Bo Chen

Stote Ellsworth

Stephen Fitzhugh Carroll

Omar Duramad

Beatrice Tien-Yi Wang

Rency Yoshimura

Leonard George Presta

Krista Maureen Mccutcheon

The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.

Modified J-chain

The present invention concerns IgA multi-specific binding molecules. In particular, the invention concerns multi-specific, including bispecific, binding molecules comprising IgA heavy chain sequences, and methods for their preparation and use.

IgA multi-specific binding molecules

This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.

Multimeric bispecific binding molecules specific for CD20 and CD3

The present invention concerns binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same. The invention further concerns multi-specific binding molecules having a penta- or hexameric ring structure, such as, for example, isolated IgM antibodies with five or six bispecific binding units, and methods and means for making and using the same.

Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies

Recombinant monoclonal antibodies to human cytomegalovirus (CMV) gB protein are described. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

High affinity human antibodies to human cytomegalovirus (CMV) gB protein

The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies, comprising the same, and their uses.

High affinity human antibodies to human cytomegalovirus (CMV) GB protein

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

Growing community of inventors

San Francisco, CA, United States of America

Fen Zhang